327 related articles for article (PubMed ID: 22450392)
21. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions.
Schieren G; Gambichler T; Skrygan M; Burkert B; Altmeyer P; Rump LC; Kreuter A
Am J Kidney Dis; 2010 Jun; 55(6):1040-9. PubMed ID: 20430497
[TBL] [Abstract][Full Text] [Related]
22. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.
Hemmatazad H; Rodrigues HM; Maurer B; Brentano F; Pileckyte M; Distler JH; Gay RE; Michel BA; Gay S; Huber LC; Distler O; Jüngel A
Arthritis Rheum; 2009 May; 60(5):1519-29. PubMed ID: 19404935
[TBL] [Abstract][Full Text] [Related]
24. New developments in the pathogenesis of systemic sclerosis.
Sakkas LI
Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of skin fibrosis in systemic sclerosis.
Jinnin M
J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
[TBL] [Abstract][Full Text] [Related]
26. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Distler O; Cozzio A
Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
[TBL] [Abstract][Full Text] [Related]
27. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
Hasegawa M
J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
[TBL] [Abstract][Full Text] [Related]
28. B cells in systemic sclerosis: a possible target for therapy.
Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
[TBL] [Abstract][Full Text] [Related]
30. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
[TBL] [Abstract][Full Text] [Related]
31. Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis.
Dimitroulas T; Daoussis D; Garyfallos A; Sfikakis PP; Kitas GD
Curr Med Chem; 2015; 22(16):1943-55. PubMed ID: 25850767
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy comes of age in scleroderma.
Denton CP; Black CM
Trends Immunol; 2005 Nov; 26(11):596-602. PubMed ID: 16168710
[TBL] [Abstract][Full Text] [Related]
33. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.
Skhirtladze C; Distler O; Dees C; Akhmetshina A; Busch N; Venalis P; Zwerina J; Spriewald B; Pileckyte M; Schett G; Distler JH
Arthritis Rheum; 2008 May; 58(5):1475-84. PubMed ID: 18438865
[TBL] [Abstract][Full Text] [Related]
34. Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis.
Beyer C; Dees C; Distler JH
Arch Dermatol Res; 2013 Jan; 305(1):1-8. PubMed ID: 23208311
[TBL] [Abstract][Full Text] [Related]
35. Future targets in the management of systemic sclerosis.
Tyndall A; Matucci-Cerinic M; Müller-Ladner U
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii49-53. PubMed ID: 19487225
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
[TBL] [Abstract][Full Text] [Related]
37. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts.
Santiago B; Galindo M; Rivero M; Pablos JL
Arthritis Rheum; 2001 Jul; 44(7):1667-76. PubMed ID: 11465719
[TBL] [Abstract][Full Text] [Related]
38. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis.
Krönke G; Reich N; Scholtysek C; Akhmetshina A; Uderhardt S; Zerr P; Palumbo K; Lang V; Dees C; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Jun; 71(6):1081-7. PubMed ID: 22267335
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
[TBL] [Abstract][Full Text] [Related]
40. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.
Leask A
Pharmacol Res; 2011 Jun; 63(6):502-3. PubMed ID: 21315153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
